Is Ketamine Therapy Covered By Insurance? State-by-State Guide

You've done the research. You know ketamine therapy might help where other treatments haven't. But now you're facing a different obstacle: figuring out whether your insurance will actually pay for it. Between confusing coverage rules, different types of ketamine, and costs that vary wildly depending on who you ask, it's hard to know where you stand financially before you even start.

The bottom line: Insurance covers FDA-approved Spravato (esketamine) through most major plans, with typical copays in the $0–$50 range per session after meeting your deductible. Off-label ketamine (IV, sublingual) is rarely covered directly, but several strategies can bring costs down, and some providers like Innerwell accept insurance through select partnerships.

What Determines Whether Your Insurance Covers Ketamine

The single biggest factor is FDA approval status. It affects whether your insurer will cover treatment, what prior authorization looks like, and even which facilities can administer it.

Traditional ketamine, whether given through an IV or dissolved under the tongue, has no FDA approval for psychiatric use. The drug is FDA-approved as an anesthetic, not as a treatment for depression or other psychiatric conditions. When doctors prescribe it for depression, anxiety, post-traumatic stress disorder (PTSD), or other conditions, that's considered "off-label," and most insurers treat off-label use as grounds to deny coverage.

Spravato (esketamine) is the exception. It is FDA-approved for adults with treatment-resistant depression, including as a monotherapy option, and for adults with major depressive disorder (MDD) with suicidal thoughts or actions when used alongside an oral antidepressant. Because of that approval, many commercial plans cover it with prior authorization. The clinical distinction between Spravato and off-label ketamine is smaller than you might expect, but from an insurance perspective, they exist in completely different worlds.

Coverage by Plan Type

Insurance categories each handle ketamine differently, which makes an already confusing process harder.

Commercial Insurance

Many large commercial insurers have medical policies that allow Spravato coverage with prior authorization, including plans offered by UnitedHealthcare, major Blue Cross Blue Shield affiliates, Cigna, and others. Aetna's medical policies consider esketamine medically necessary for specific labeled indications such as treatment-resistant depression and major depressive disorder with acute suicidal ideation or behavior when criteria are met; other indications are classified as experimental or investigational. Coverage varies by specific plan, so it's worth checking with your insurer before starting treatment.

Insurers often approve coverage for a defined period (commonly 6–12 months) and require documented continued benefit for renewal. If you have treatment-resistant depression, your history of trying multiple medications is likely what qualifies you. Most insurers require documentation that you've tried at least two antidepressants from different drug classes without adequate improvement, along with baseline scores from a validated assessment like the Patient Health Questionnaire (PHQ-9) or the Montgomery-Åsberg Depression Rating Scale (MADRS). The treatment facility also matters: both your provider and facility must be certified through the Spravato Risk Evaluation and Mitigation Strategy (REMS) program, a mandatory FDA safety protocol. Insurance won't cover treatment at a facility that isn't REMS-certified.

For off-label IV ketamine, commercial coverage is extremely rare. Most insurers classify it as "investigational." A small number of health plans have begun covering IV ketamine in specific cases, but these remain exceptions. Mass General Brigham Health Plan publishes a medical policy that considers intravenous ketamine medically necessary for members 18 and older with treatment-resistant major depressive disorder or severe suicidal ideation when strict criteria are met; IV ketamine is considered investigational for other indications.

Medicare

Medicare covers Spravato under Part B when administered in a certified setting. Under Original Medicare, after meeting the annual Part B deductible, Medicare typically covers 80% of the approved amount, with the remaining 20% as your coinsurance. A Medigap plan may reduce or eliminate that 20%. If you have Medicare Advantage, cost-sharing may differ, so call your plan to confirm. Off-label ketamine is generally not covered.

Medicaid and VA

Medicaid coverage varies by state and can change quickly. Many state Medicaid programs cover Spravato when strict medical-necessity criteria are met, but coverage rules and prior authorization requirements differ significantly from state to state. If you're on Medicaid, call your state Medicaid office or managed care plan to ask about current coverage and criteria.

Some VA facilities have also begun offering Spravato for veterans with treatment-resistant depression, though availability varies by medical center. Your local VA mental health department can tell you what's currently available.

What You'll Actually Pay

The price ranges you'll find online can be overwhelming, especially when you're already weighing treatment decisions. Here's what most people actually pay, and what those numbers include.

Spravato requires twice-weekly sessions during induction with mandatory in-clinic monitoring, so even with insurance, the time commitment adds up. At-home sublingual programs eliminate travel and monitoring wait times, which matters if you're managing work, family, or chronic pain on top of treatment.

Even when ketamine medication itself isn't covered, surrounding services often are. Initial consultations, lab work, follow-up visits, and psychotherapy sessions may be reimbursable when documented as medically necessary. If your provider bundles therapy into the program (as Innerwell does), the therapy component may qualify for separate reimbursement.

If you have a Health Savings Account (HSA) or Flexible Spending Account (FSA), ketamine therapy may qualify as an eligible medical expense when prescribed by a licensed provider. Check with your plan administrator, since using pre-tax dollars can reduce your effective cost.

For a deeper look at what drives ketamine pricing, see the full cost breakdown.

How to Get Coverage or Overturn a Denial

Fighting for insurance coverage when you're already dealing with treatment-resistant depression isn't fair, but it's navigable. If you're pursuing Spravato coverage or appealing a denial, these steps give you the best chance.

Build a strong prior authorization request

A strong request starts with your prescriber's letter of medical necessity. It should include your full medication trial history (which drugs, what dosages, how long, why they didn't work), a clinical rationale for ketamine, and your baseline assessment scores. The more specific and well-documented, the better your chances of first-pass approval.

Check for patient assistance programs

Janssen's Spravato withMe savings program can reduce what you pay. If you have commercial insurance, you may pay as little as $10 per treatment for Spravato medication costs through the program. Separate manufacturer assistance programs may be available if you're uninsured; check the official program website for current terms.

Submit out-of-network claims with a superbill

If your plan includes out-of-network benefits, you may be able to submit claims for partial reimbursement of off-label ketamine treatment. Ask your provider for a superbill, a detailed receipt with the billing codes insurers need for processing. Before you submit, call your insurer and ask about your out-of-network deductible and reimbursement percentage so you know what to realistically expect back.

Appeal denials formally

Every state gives you the right to appeal. The most effective appeals are specific: include the written denial reason, your documented treatment history, and a clinician-backed rationale explaining why this treatment is medically necessary for your situation.

One tool worth knowing: the mental health parity law, formally the Mental Health Parity and Addiction Equity Act (MHPAEA), requires insurers to apply the same standards to mental health coverage as they do to physical health coverage. If your insurer denies Spravato but covers similarly expensive medications for physical conditions, referencing parity standards can strengthen your case.

If an internal appeal fails, most states allow you to request an independent external review by a third-party organization, and the insurer is legally required to abide by that reviewer's decision. Ask your insurer or state department of insurance about the process.

For more cost-reduction strategies, see the guide to affordable ketamine.

How Innerwell's At-Home Ketamine Therapy Works

If clinic visits mean transportation hassles, uncertain costs, and hours of mandatory monitoring, at-home ketamine therapy offers a simpler path. This isn't a medication-only service that ships tablets and leaves you to figure it out. Every step includes clinical guidance from professionals who specialize in ketamine-assisted treatment.

Innerwell pairs sublingual ketamine tablets with licensed psychiatric providers and licensed psychotherapists, all of whom hold Master's or Doctoral degrees.

The process:

1. Evaluation: A psychiatric assessment reviews your medical history, determines whether ketamine fits your situation, and shapes a personalized treatment plan.
2. Delivery: Your medication ships directly to your home with adult-signature verification and precise dosing instructions. No clinic visits, no arranging rides, no mandatory waiting rooms.
3. Preparation and integration: Licensed therapists guide intention-setting before each session and work with you to process insights afterward. Ketamine opens a window of neuroplasticity; integration therapy turns that window into lasting change.
4. Ongoing monitoring: Your care team tracks progress, adjusts dosing, and coordinates with other providers when needed.

Pricing

• Foundation Plan (8 doses): $599 with insurance ($75/treatment) or $998 self-pay ($125/treatment)
• Extended Plan (24 doses): $1,299 with insurance ($54/treatment) or $1,999 self-pay ($83/treatment)

Innerwell accepts insurance in California and New York, with superbills available for out-of-network reimbursement.

Clinical Outcomes

People who complete treatment through Innerwell see a 69% average reduction in depression symptoms after 10 weeks and a 60% reduction in anxiety symptoms over the same period. 87% improve within four weeks, with a 4.7 out of 5 satisfaction rating (based on Innerwell internal outcomes data).

Take the free assessment to see if ketamine therapy might work for you.

Frequently Asked Questions

What if my insurer denies coverage for Spravato?

Start with a formal internal appeal, including your full treatment history and a letter of medical necessity from your prescriber. If that fails, request an independent external review through your state. If you've previously completed off-label ketamine and seen documented improvement, those outcomes can support your case.

Can I switch insurance plans to get ketamine coverage?

Yes, but only during open enrollment (typically November through January) or after a qualifying life event. Before switching, call the plan's benefits line and ask specifically about esketamine (Spravato) coverage for treatment-resistant depression, including prior authorization requirements and copay amounts.

Will insurance ever cover IV ketamine for depression?

It's possible but unlikely in the near term. Until IV ketamine receives its own FDA approval for psychiatric use, most insurers will continue classifying it as investigational.

What if I can't afford any ketamine treatment right now?

Cost shouldn't be what keeps you from getting help, and there are more options than you might think. HSA or FSA funds can reduce costs through pre-tax savings. Medical financing options like CareCredit offer payment plans for healthcare expenses. Some people begin with a shorter introductory program to test their response before committing to a full protocol, and documenting even partial improvement creates useful evidence for future insurance appeals.